Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > NOPE again

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon Jan 19, 2022 10:56am

99 Views

Post# 34332660

NOPE again

You quoted the website: "“Claritas Pharmaceuticals is an innovative biotech company developing R-107 for the treatment of vaccine-resistant COVID strains.”

As far as I know the Salzman group are the only ones who have any R107 product and there is no active developement going on at this point that I have heard of ....so no not fundamental info

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec